Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of The Cancer Genome Atlas confirmed a relationship between glioma NF1 status and ENG and CHI3L1 in tumor samples.
|
29643433 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ-resistant relapsed gliomas.
|
28031240 |
2017 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas).
|
27121858 |
2016 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate, in a small series of three GCAs, the expression of mesenchymal/radioresistance-associated biomarkers [such as chitinase-3-like protein 1 (YKL-40), hepatocyte growth factor receptor (c-Met), and caveolin 1 (Cav1)] that could contribute to the poor outcome associated with this glioma subgroup.
|
26845757 |
2016 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our gene analysis revealed that in general, YKL40 mRNA in glioma patients was over-expressed versus normal brain.
|
25629266 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thus, targeting the CHI3L1 molecule may be a potential therapeutic molecular target for gliomas.
|
20506295 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that CHI3L1 plays an important role in the regulation of malignant transformation and local invasiveness in gliomas.
|
20506295 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40.
|
21953450 |
2011 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations.
|
20224722 |
2010 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 may be an attractive target for glioma therapy.
|
20499402 |
2010 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
|
20174854 |
2010 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CHI3L2, IL1B, PI3/elafin and CHI3L1, which encodes for YKL-40, a putative prognosticator for various diseases, including cancer, were strongly up-regulated in avascular glioma.
|
18092325 |
2008 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Even though TNF-alpha causes recruitment of p65 and p50 subunits of NF-kappaB to the YKL-40 promoter in all cell types, recruitment of histone deacetylases (HDAC)-1 and -2, and a consequent deacetylation of histone H3 at the YKL-40 promoter occurs only in glioma cells.
|
18708058 |
2008 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
|
18708058 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Anaplastic glioma patients with no radiographic evidence of disease (n = 32 patients, 107 samples) also had a significantly lower level of YKL-40 compared with those patients with active tumor (n = 48 patients, 199 samples; P = 0.04).
|
17020973 |
2006 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas.
|
15788675 |
2005 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis of glioma samples for YKL-40 protein levels revealed substantial elevation in approximately 65% of GBMs and undetectable levels in lower-grade gliomas (grade II and III) or normal brain tissue.
|
12154041 |
2002 |